Interim report, January - June, 2008

Interim report, January - June, 2008

Key events in the second quarter
• AbSorber is granted U.S. patent for AB0 column
• IMED's core patent is granted protection in Europe
• Bridging Business Development AB invests in Pharmacolog
• Anders Karlsson takes over CEO position at AbSorber
• ONCOlog strengthens organization with new CFO
• Birgitta Gunneflo elected to the LinkMed Board of Directors

Comments from LinkMed CEO Ingemar Lagerlöf on the second quarter 2008:
”It has been an intensive six months in which the most significant events were
communicated after the half-year mark. The acquisition of Olerup SSP AB is
interesting for a number of reasons. It is a well-run and extremely profitable
company active in what is for us an interesting and growing market. From a
financial perspective, it means positive business results for us. Furthermore,
the acquisition gives us the opportunity to build a unique company in the
transplantation sector in collaboration with AbSorber. The FDA's approval of
XM-ONE® strengthens AbSorber's position and opens up the important U.S. market,
which is very positive going forward.”


LinkMed develops life-science companies in collaboration with innovators and
other financiers. By contributing entrepreneurship and capital, LinkMed has
created a portfolio of eleven companies, six in drug development and five in
medical technology. LinkMed's role changes as its portfolio companies develop.
The emphasis moves from operational to strategic and the entrepreneurship role
evolves into active Board work.